16 October 2015 - AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a complete response letter regarding the new drug application for the investigational fixed-dose combination of saxagliptin and dapagliflozin for the treatment of adult patients with type 2 diabetes.

For more details, go to: http://www.astrazeneca.com/Media/Press-releases/Article/20151016--astrazeneca-receives-complete-response-letter-from-us